Page last updated: 2024-11-12
nb 506
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
NB 506: an indolocarbazole antitumor agent; structure given in first source; a DNA topoisomerase I inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 9915861 |
| CHEMBL ID | 2074831 |
| SCHEMBL ID | 5481070 |
| MeSH ID | M0244090 |
Synonyms (15)
| Synonym |
|---|
| CHEMBL2074831 |
| SCHEMBL5481070 |
| 6-n-formylamino-12,13-dihydro-1,11-dihydroxy-13-(beta-d-glucopyranosyl)-5h-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6h)-dione |
| nb-506 |
| n-[5,21-dihydroxy-12,14-dioxo-3-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17(22),18,20-nonaen-13-yl]formamide |
| formamide, n-(12-.beta.-d-glucopyranosyl-5,7,12,13-tetrahydro-1,11-dihydroxy-5,7-dioxo-6h-indolo(2,3-a)pyrrolo(3,4-c)carbazol-6-yl)- |
| 6-n-formylamino-12,13-dihydro-1,11-dihydroxy-13-(.beta.-d-glucopyranosyl) 5h-indolo (2,3-a)pyrrolo (3,4-c)carbazole-5,7(6h)-dione |
| n-(12-.beta.-d-glucopyranosyl-5,7,12,13-tetrahydro-1,11-dihydroxy-5,7-dioxo-6h-indolo(2,3-a)pyrrolo(3,4-c)carbazol-6-yl)formamide |
| unii-q7sf8h5tf6 |
| n-(12-beta-d-glucopyranosyl-5,7,12,13-tetrahydro-1,11-dihydroxy-5,7-dioxo-6h-indolo(2,3-a)pyrrolo(3,4-c)carbazol-6-yl)formamide |
| 151069-12-4 |
| q7sf8h5tf6 , |
| 6-n-formylamino-12,13-dihydro-1,11-dihydroxy-13-(beta-d-glucopyranosyl) 5h-indolo (2,3-a)pyrrolo (3,4-c)carbazole-5,7(6h)-dione |
| nb 506 |
| formamide, n-(12-beta-d-glucopyranosyl-5,7,12,13-tetrahydro-1,11-dihydroxy-5,7-dioxo-6h-indolo(2,3-a)pyrrolo(3,4-c)carbazol-6-yl)- |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " Cytotoxicity measurements performed with various human cancer cell lines (HCT-116, DLD-1, MKN-45) indicate that the newly designed drug is 3 to 4 times more toxic to colon and gastric cancer cells than NB-506." | ( Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities. Bailly, C; Chaires, JB; Colson, P; Houssier, C; Nishimura, S; Ohkubo, M; Qu, X; Yoshinari, T, 1999) | 0.3 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (1)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID681276 | TP_TRANSPORTER: intracellular accumulation in LY and LY/NR2 cells | 2001 | Cancer research, Apr-01, Volume: 61, Issue:7 | Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (28)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 22 (78.57) | 18.2507 |
| 2000's | 6 (21.43) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 18.64
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (18.64) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (3.33%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 29 (96.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||